Physician profile
Richard Bennett
NPI 1821053026
$14,255.33
in general payments reported to CMS, 2019-2025
30 companies · $2,864 in 2025
The $2,864 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $1,505 · 2021: $1,926 · 2022: $1,911 · 2023: $2,648 · 2024: $2,498 · 2025: $2,864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,009.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,873.79 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,399.13 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $1,380.88 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $1,024.96 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $1,016.47 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $1,011.47 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $797.13 | 2019-2025 | Trintellix |
| Allergan, INC. | $637.71 | 2019-2020 | |
| Bausch Health US, LLC | $588.86 | 2020-2024 | Wellbutrin, Aplenzin |
| Axsome Therapeutics, INC. | $493.07 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $482.03 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $399.61 | 2020-2024 | Caplyta |
| Idorsia Pharmaceuticals US INC | $315.96 | 2022-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $282.84 | 2021-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $256.86 | 2023-2025 | Fanapt, Hetlioz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $213.54 | 2022-2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $191.23 | 2021-2022 | |
| Alfasigma USA, INC. | $171.45 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $129.35 | 2021-2023 | Belsomra |
| Almatica Pharma LLC | $114.16 | 2022-2025 | Loreev Xr |
| Neos Therapeutics, Lp | $91.92 | 2019-2020 | |
| Eisai INC. | $91.63 | 2020-2022 | |
| Biogen, INC. | $85.06 | 2025 | Zurzuvae |
| Noven Therapeutics, LLC | $42.28 | 2020-2024 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $40.81 | 2025 | Cobenfy |
| Novartis Pharmaceuticals Corporation | $38.94 | 2019 | |
| Collegium Pharmaceutical, INC. | $29.06 | 2025 | Jornay Pm |
| Sun Pharmaceutical Industries INC. | $23.29 | 2020 | |
| Novo Nordisk INC | $17.43 | 2023 | Wegovy |
| Ironshore Pharmaceuticals INC. | $14.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.